A pharma giant is moving past one patent cliff but another is already looming
">
A pharma giant is moving past one patent cliff but another is already looming
Disappointing data highlights Novartis’ challenge to build its next generation of blockbuster medicines, following a series of clinical trial setbacks.
This article was created based on information from various sources and rewritten for clarity and originality.
